News Release

Significant progress on validations and IND filing

Date: October 23, 2000

CDNX Trading Symbol: WXI
World Wide Web: http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc., (the "Company") is pleased to announce that 2 more positive events have occurred.

1. As previously announced, the Company undertook to validate a relative 7 samples of the numerous tests that were performed in China at qualified laboratories in Canada.
   
   The Company is pleased to confirm that in addition to the 4 positive confirmations already completed, the fifth and sixth can now be added. These 2 validations addressed the toxicity studies on the Wistar rats. The variance of the results obtained in China and what was obtained here are well within the acceptable tolerance ranges. The only validation test still outstanding is also one on the Wistar rats and also relates to toxicity. This last test is referred to as a multi-dose ranging study and should clearly indicate a safe range for humans. The results should be in written report form for the Company sometime during December. These toxicity studies relate to the starting point for the assessment of safety on using Tetrodin (the Company's pharmaceutical product) for ultimate use in humans via intra-muscular injection doses.
2. The Company made an announcement at the beginning of October, 2000 that an IND submission to Health Protection Branch (HPB) Canada had been filed. We are very pleased to confirm that the application has passed stage one and is now at the 'reviewing' stage. This initial stage occurs once a submission has been made and all documentation is reviewed to ensure that all the requirements and information is presented as requested by HPB and in the proper format, adequate copies, etc.
   
   These 2 steps are further encouraging milestones for the Company.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per:Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.